KJKathryn S. Jones

Kathryn S. Jones

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Kathryn S. Jones has a total of 51 co-authors. Here are the top co-authors by number of shared publications:

  • Cari Petrow-Sadowski

    Basic Research Program, Cancer and Inflammation Program, SAIC-Frederick, Inc., Frederick National Laboratory for Cancer Research, Frederick, Maryland, USA

    6 shared publications
  • Claudine Pique

    INSERM U1016, CNRS UMR 8104, Université Paris Descartes, Sorbonne Paris Cité, Institut Cochin, Paris, France

    4 shared publications
  • Daniel C Bertolette

    Cancer and Inflammation Program, Center for Cancer Research, National Cancer Institute, Frederick, Maryland, USA

    3 shared publications
  • Francis W Ruscetti

    Cancer and Inflammation Program, Center for Cancer Research, National Cancer Institute, Frederick, Maryland, USA

    3 shared publications
  • Francis W. Ruscetti

    Laboratory of Experimental Immunology, Cancer and Inflammation Program, Center for Cancer Research, National Cancer Institute, Frederick, MD

    3 shared publications
  • Daniel C. Bertolette

    Basic Science Program, SAIC-Frederick, Inc,1 Laboratory of Experimental Immunology, Cancer and Inflammation Program, Center for Cancer Research, NCI-Frederick, Frederick, Maryland,2 Unité d'Epidémiologie et Physiopathologie des Virus Oncogènes, Département de Virologie, Institut Pasteur, Paris, France,3 The George Washington University Medical Center, Washington, DC4

    2 shared publications

Latest Publications

  • Open Access

    Conference Highlights of the 16th International Conference on Human Retrovirology: HTLV and Related Retroviruses, 26–30 June 2013, Montreal, Canada

    by Benoit Barbeau, John Hiscott, Ali Bazarbachi, Edgar Carvalho, Kathryn Jones, Fabiola Martin, Masao Matsuoka, Edward L Murphy, Lee Ratner, William M Switzer, et al.

    The 16th International Conference on Human Retrovirology: HTLV and Related Retroviruses was held in Montreal, Québec from June 26th to June 30th, 2013 and was therefore hosted by a Canadian city for the first time. The major topic of the meeting was human T-lymphotropic viruses (HTLVs) and was covered through distinct oral and poster presentation sessions: clinical research, animal models, immunology, molecular and cellular biology, human endogenous and emerging exogenous retroviruses and virology. In this review, highlights of the meeting are provided by different experts for each of these research areas.


  • Open Access

    Different routes of entry of HTLV-1 during infection of primary dendritic cells and CD4+ T cells

    by Kathryn S Jones, Cari Petrow-Sadowski, Daniel C Bertolette, Nabela Enam, Rachel K Bagni, Stig Mr Jensen, David A Davis, Robert Yarchoan, Francis W Ruscetti


  • Open Access

    Pathways of cell-cell transmission of HTLV-1

    by Claudine Pique, Kathryn S. Jones

    The deltaretroviruses human T cell lymphotropic virus type 1 (HTLV-1) and human T cell lymphotropic virus type 2 (HTLV-2) have long been believed to differ from retroviruses in other genera by their mode of transmission. While other retroviruses were thought to primarily spread by producing cell-free particles that diffuse through extracellular fluids prior to binding to and infecting target cells, HTLV-1 and HTLV-2 were believed to transmit the virus solely by cell–cell interactions. This difference in transmission was believed to reflect the fact that, relative to other retroviruses, the cell-free virions produced by HTLV-infected cells are very poorly infectious. Since HTLV-1 and HTLV-2 are primarily found in T cells in the peripheral blood, spread of these viruses was believed to occur between infected and uninfected, T cells, although little was known about the cellular and viral proteins involved in this interaction. Recent studies have revealed that the method of transmission of HTLV is not unique: other retroviruses including human immunodeficiency virus (HIV) are also transmitted from cell-to-cell, and this method is dramatically more efficient than cell-free transmission. Moreover, cell–cell transmission of HTLV-1, as well as HIV, can occur following interactions between dendritic cells and T cells, as well as between T cells. Conversely, other studies have shown that cell-free HTLV-1 is not as poorly infectious as previously thought, since it is capable of infecting certain cell types. Here we summarize the recent insights about the mechanisms of cell–cell transmission of HTLV-1 and other retroviruses. We also review in vitro and in vivo studies of infection and discuss how these finding may relate to the spread of HTLV-1 between individuals.


  • Open Access

    Molecular Aspects of HTLV-1 Entry: Functional Domains of the HTLV-1 Surface Subunit (SU) and Their Relationships to the Entry Receptors

    by Kathryn S. Jones, Sophie Lambert, Manuella Bouttier, Laurence Bénit, Frank W. Ruscetti, Olivier Hermine, Claudine Pique

    The initial step in retroviral infection involves specific interactions between viral envelope proteins (Env) and specific receptors on the surface of target cells. For many years, little was known about the entry receptors for HTLV-1. During this time, however, functional domains of the HTLV-1 Env were identified by analyzing the effects of neutralizing antibodies and specific mutations in Env on HTLV-1 infectivity. More recent studies have revealed that HTLV-1 infectivity involves interactions with three different molecules: heparan sulfate proteoglycans (HSPG), the VEGF-165 receptor Neuropilin 1 (NRP-1) and glucose transporter type 1 (GLUT1). Here, we revisit previously published data on the functional domains of Env in regard to the recent knowledge acquired about this multi-receptor complex. We also discuss the similarities and differences between HTLV-1 and other deltaretroviruses in regards to receptor usage.


  • Open Access

    Continuous long-term growth of plasmacytoid dendritic cells following in vitro infection with HTLV-1

    by Kathryn S Jones, Daniel C Bertolette, Xue T Bai, Cari Petrow-Sadowski, Tao Fu, Genoveffa Franchini, Christophe Nicot, Francis W Ruscetti


  • Open Access

    Current concepts regarding the HTLV-1 receptor complex

    by David Ghez, Yves Lepelletier, Kathryn S Jones, Claudine Pique, Olivier Hermine

    The identity of the Human T lymphotropic Virus type 1 (HTLV-1) receptor remained an unsolved puzzle for two decades, until the recent demonstration that three molecules, Glucose Transporter 1, Neuropilin-1 and Heparan Sulfate Proteoglycans are involved in HTLV-1 binding and entry. Despite these advances, several questions remain unanswered, including the precise role of each of these molecules during virus entry. In light of the most recent data, we propose a model of the HTLV-1 receptor complex and discuss its potential impact on HTLV-1 infection.


  • Cloaked virus slips between cells

    by Kathryn S Jones, Patrick L Green

    A common retrovirus encases itself in an extracellular matrix, enabling its transfer between T4 cells. The discovery of this new mode of infectivity has the potential to lead to new ways to combat the virus, human T cell leukemia virus type 1 (HTLV-1), which is associated with cancers and inflammatory disorders (pages 83–89 ).


  • Open Access

    HTLV-1 uses HSPG and neuropilin-1 for entry by molecular mimicry of VEGF165

    by Sophie Lambert, Manuella Bouttier, Roger Vassy, Michel Seigneuret, Cari Petrow-Sadowski, Sébastien Janvier, Nikolaus Heveker, Francis W. Ruscetti, Gérard Perret, Kathryn S. Jones, et al.

    Human T-cell lymphotropic virus type 1 (HTLV-1) entry involves the interaction between the surface (SU) subunit of the Env proteins and cellular receptor(s). Previously, our laboratories demonstrated that heparan sulfate proteoglycans (HSPGs) and neuropilin-1 (NRP-1), a receptor of VEGF165, are essential for HTLV-1 entry. Here we investigated whether, as when binding VEGF165, HSPGs and NRP-1 work in concert during HTLV-1 entry. VEGF165 binds to the b domain of NRP-1 through both HSPG-dependent and -independent interactions, the latter involving its exon 8. We show that VEGF165 is a selective competitor of HTLV-1 entry and that HTLV-1 mimics VEGF165 to recruit HSPGs and NRP-1: (1) the NRP-1 b domain is required for HTLV-1 binding; (2) SU binding to target cells is blocked by the HSPG-binding domain of VEGF165; (3) the formation of Env/NRP-1 complexes is enhanced by HSPGs; and (4) the HTLV SU contains a motif homologous to VEGF165 exon 8. This motif directly binds to NRP-1 and is essential for HTLV-1 binding to, internalization into, and infection of CD4+ T cells and dendritic cells. These findings demonstrate that HSPGs and NRP-1 function as HTLV-1 receptors in a cooperative manner and reveal an unexpected mimicry mechanism that may have major implications in vivo.


  • Open Access

    The Receptor Complex Associated with Human T-Cell Lymphotropic Virus Type 3 (HTLV-3) Env-Mediated Binding and Entry Is Distinct from, but Overlaps with, the Receptor Complexes of HTLV-1 and HTLV-2

    by Kathryn S. Jones, Ying K. Huang, Sébastien A. Chevalier, Philippe V. Afonso, Cari Petrow-Sadowski, Daniel C. Bertolette, Antoine Gessain, Francis W. Ruscetti, Renaud Mahieux

    Little is known about the transmission or tropism of the newly discovered human retrovirus, human T-cell lymphotropic virus type 3 (HTLV-3). Here, we examine the entry requirements of HTLV-3 using independently expressed Env proteins. We observed that HTLV-3 surface glycoprotein (SU) binds efficiently to both activated CD4+ and CD8+ T cells. This contrasts with both HTLV-1 SU, which primarily binds to activated CD4+ T cells, and HTLV-2 SU, which primarily binds to activated CD8+ T cells. Binding studies with heparan sulfate proteoglycans (HSPGs) and neuropilin-1 (NRP-1), two molecules important for HTLV-1 entry, revealed that these molecules also enhance HTLV-3 SU binding. However, unlike HTLV-1 SU, HTLV-3 SU can bind efficiently in the absence of both HSPGs and NRP-1. Studies of entry performed with HTLV-3 Env-pseudotyped viruses together with SU binding studies revealed that, for HTLV-1, glucose transporter 1 (GLUT-1) functions at a postbinding step during HTLV-3 Env-mediated entry. Further studies revealed that HTLV-3 SU binds efficiently to naïve CD4+ T cells, which do not bind either HTLV-1 or HTLV-2 SU and do not express detectable levels of HSPGs, NRP-1, and GLUT-1. These results indicate that the complex of receptor molecules used by HTLV-3 to bind to primary T lymphocytes differs from that of both HTLV-1 and HTLV-2.


  • Cell-free HTLV-1 infects dendritic cells leading to transmission and transformation of CD4+ T cells

    by Kathryn S Jones, Cari Petrow-Sadowski, Ying K Huang, Daniel C Bertolette, Francis W Ruscetti

    Cell-free human T-lymphotropic virus type 1 (HTLV-1) virions are poorly infectious in vitro for their primary target cells, CD4(+) T cells. Here, we show that HTLV-1 can efficiently infect myeloid and plasmacytoid dendritic cells (DCs). Moreover, DCs exposed to HTLV-1, both before and after being productively infected, can rapidly, efficiently and reproducibly transfer virus to autologous primary CD4(+) T cells. This DC-mediated transfer of HTLV-1 involves heparan sulfate proteoglycans and neuropilin-1 and results in long-term productive infection and interleukin-2-independent transformation of the CD4(+) T cells. These studies, along with observations of HTLV-1-infected DCs in the peripheral blood of infected individuals, indicate that DCs have a central role in HTLV-1 transmission, dissemination and persistence in vivo. In addition to altering the current paradigm concerning how HTLV-1 transmission occurs, these studies suggest that impairment of DC function after HTLV-1 infection plays a part in pathogenesis.